THE UNITED STATES PATENT AND TRADEMARK OFFICE ation of : Bechtold-Peters, K.) Art Unit: 1615 U.S. Appln. No. : 10/054,592) Examiner: Confirmation No.: 7703 U.S. Filing Date : January 22, 2002 Title of Invention: Medical Formulation Containing a Muscarinic Agonist Attny. Docket No.: 1/1187 Commissioner for Patents Washington, D.C. 20231 November 14, 2002 TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT Sir: Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow. X This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114. 1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by: A statement as specified in 37 C.F.R. §1.97(e) [see below]; or The fee set forth in 37 C.F.R. §1.17(p).

02-2955.

\$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No.

The Commissioner is hereby authorized to charge payment of the

\$1.97(0 statemo \$1.17(1	1.97(d). This Statement is being filed after the period specified in 37 C.F.R. c) but on or before payment of the issue fee. This Statement is accompanied by a ent as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. p).
	1.97(e).
	Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or
	No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.
	The fee set forth in 37 C.F.R. §1.17(p).
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
disclosu counterj in section	1.704(d). Each item of information contained in the accompanying information are statement was cited in a communication from a foreign patent office in a part application, which communication was not received by any individual designated on 1.56(c) more than thirty (30) days prior to the filing of the accompanying tion disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing quired under 37 C.F.R. §1.16 and any patent application processing fees under 37 §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

ate copies of this form are enclosed.

Respectfully submitted, fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Timothy X. Witkewski Attorney for Applicant(s)

I hereby certify that this correspondence is being

Reg. No. 40,232

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT. 06877 Tel.: (203) 798-4310

deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner for Patents

Washington, DC 20231

on November 14, 2002

By: Timothy X. Withowski

Reg. No. . 40,232

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449A/PTO

NOV 1 9 2002

TRADEN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complet if Kn wn			
Application Number	10/054,592		
Filing Date	January 22, 2002		
First Named Inventor	Bechtold-Peters, K. et al		
Art Unit	1615		
Examiner Name	To be assigned		
Attorney Docket Number	1/1187		

			U.S. PATE	NT DOCUMENTS	
Examiner Initials		Document Number Number- Kind Code ² (if known	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			194.001.000
		US-	***************************************		***************************************
		US-			
		US-	terretere second a stra summa una	and the second s	` ^
		US-			
		US-			
		us-			Co N. C.
**************************************		US-			C/2 0/2
	**************************************	US-		The state of the s	Co. 2 11
		US-			1/2
	100	US-			(%) P2
		US-			1000
		US-			() () () () () () () () () ()
		US-			20-
	*	US-		7,	
***	********	US-			
nnanasana a		US-		77 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	
		US-		**************************************	***************************************
		US-			
		US-		, , , , , , , , , , , , , , , , , , ,	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code 3 -Number 4 - Kind Code 5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
**** *** *** ** ** *********		DE 198 51 126 A1	11/05/2000	Boehringer Ingelheim Pharma KG		
		EP 0 370 415	05/30/1990	Boehringer Ingelheim		
- 04 - 1		WO98/30243 WO 98/46601	07/16/1998 10/22/1998	Warner-Lambert Eli Lilly and Co.		
		WO 98/46225	10/22/1998	Eli Lilly and Co.		
					transmit leiktroken om for patietersverskeningspiegregerige bliger (like	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional).

2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

6 Applicant is to place a check mark here if English language Translation is attached.